Inhibikase Therapeutics, Inc.
IKT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $8 | $5 | $11 | $7 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $6 | $6 | $5 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$1 | $0 |
| Operating Expenses | $13 | $11 | $15 | $13 |
| Operating Income | -$13 | -$11 | -$15 | -$13 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | $1 | $1 |
| Pre-Tax Income | -$12 | -$10 | -$14 | -$12 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12 | -$10 | -$14 | -$12 |
| % Margin | – | – | – | – |
| EPS | -0.133 | -0.11 | -0.15 | -0.17 |
| % Growth | -20.5% | 26.7% | 11.8% | – |
| EPS Diluted | -0.133 | -0.11 | -0.15 | -0.17 |
| Weighted Avg Shares Out | 90 | 90 | 90 | 69 |
| Weighted Avg Shares Out Dil | 90 | 90 | 90 | 69 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$12 | -$11 | -$16 | -$12 |
| % Margin | – | – | – | – |